Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose
gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients
who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a
gemcitabine-containing regimen).